Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
US7294468B2 · kind B2 · utility
165Cited by
0References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 5, 2005 |
| Grant date | Nov 13, 2007 |
| Priority date | — |
| Expiry date | Dec 5, 2025 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.